Re-Emergence of DENV-3 in French Guiana: Retrospective Analysis of Cases That Circulated in the French Territories of the Americas from the 2000s to the 2023-2024 Outbreak

Viruses. 2024 Aug 14;16(8):1298. doi: 10.3390/v16081298.

Abstract

French Guiana experienced an unprecedented dengue epidemic during 2023-2024. Prior to the 2023-2024 outbreak in French Guiana, DENV-3 had not circulated in an epidemic manner since 2005. We therefore studied retrospectively the strains circulating in the French Territories of the Americas (FTA)-French Guiana, Guadeloupe, and Martinique-from the 2000s to the current epidemic. To this end, DENV-3 samples from the collection of the National Reference Center for Arboviruses in French Guiana (NRCA-FG) were selected and sequenced using next-generation sequencing (NGS) based on Oxford Nanopore Technologies, ONT. Phylogenetic analysis showed that (i) the 97 FTA sequences obtained all belonged to genotype III (GIII); (ii) between the 2000s and 2013, the regional circulation of the GIII American-I lineage was the source of the FTA cases through local extinctions and re-introductions; (iii) multiple introductions of lineages of Asian origin appear to be the source of the 2019-2021 epidemic in Martinique and the 2023-2024 epidemic in French Guiana. Genomic surveillance is a key factor in identifying circulating DENV genotypes, monitoring strain evolution, and identifying import events.

Keywords: DENV monitoring; DENV-3; NGS; molecular epidemiology; re-emergence.

MeSH terms

  • Dengue Virus* / classification
  • Dengue Virus* / genetics
  • Dengue Virus* / isolation & purification
  • Dengue* / epidemiology
  • Dengue* / virology
  • Disease Outbreaks*
  • French Guiana / epidemiology
  • Genotype*
  • Guadeloupe / epidemiology
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Martinique / epidemiology
  • Phylogeny*
  • RNA, Viral / genetics
  • Retrospective Studies

Substances

  • RNA, Viral

Grants and funding

This work was financed by the NRCA-FG. The activity of the National Reference Centers is supported by the French National Health Agency (Santé Publique France).